Introduction: B-Lymphocyte Stimulator (BLyS) was recently involved in the regulation of malignant cell survival cancers.
Aim(s): To test BLyS as a new serological marker in the follow-up of patients with neuroendocrine tumors (NET).
Materials and methods: Eighty-one consecutive patients with NET and 56 sex-matched controls enrolled in the study. Patients were classified in two subgroups according to clinical course: evidence of persistent but stable disease or in remission (n=45) and patients with evidence of recurrent disease (n=36). BLyS and Chromogranin A (CgA) serum levels were analyzed by ELISA.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Dr Franco Grimaldi
To read results and conclusion, please login ...
Further abstracts you may be interested in